ACBI1 Agonist A significant increase of the

A significant increase of the animal lifespan in the test groups (from 4

Ocular hypotensive efficacy

is a n orally available PLK1 inhibitor with potential antineoplastic activity

it has a yellow crystalline appearance

InChi: InChI=1S/C29H43NO4S/c1-17(2)22-14-25(20(7)8)27(26(15-22)21(9)10)16-28(31)30-35(32

ACBI1 Agonist A significant increase of theACBI1 is a potent PROTAC degrader of BAF ATPase subunits SMARCA2 and SMARCA4, also degrades the polybromo associated BAF (PBAF) complex member PBRM1, with DC50s of 6 nM, 11 nM and 32 nM for SMARCA2, SMARCA4 and PBRM1 in MV 4 11 cells, respectively. ACBI1 is composed of a bromodomain ligand, a linker, and the E3 ubiquitin ligase VHL. ACBI1 can induce anti proliferative effects and apoptosis. Product information CAS Number: 2375564 55 7 Molecular